EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 21st, 2023 • Centene Corp • Hospital & medical service plans • Missouri
Contract Type FiledFebruary 21st, 2023 Company Industry JurisdictionIn this Executive Employment Agreement, dated as of February 20, 2023 (the “Agreement”), Centene Corporation (the “Company”), and Kenneth Fasola (the “Executive”), intending to be legally bound and for good and valuable consideration, agree as follows:
CENTENE CORPORATION Restricted Stock Agreement Granted Under 2012 Stock Incentive PlanRestricted Stock Agreement • February 21st, 2023 • Centene Corp • Hospital & medical service plans • Delaware
Contract Type FiledFebruary 21st, 2023 Company Industry JurisdictionTHIS AGREEMENT is entered into by Centene Corporation, a Delaware corporation (hereinafter the “Company”), and the undersigned Director of the Company (hereinafter the “Participant”).
CENTENE CORPORATION Nonstatutory Stock Option Agreement Granted Under 2012 Stock Incentive PlanNonstatutory Stock Option Agreement • February 21st, 2023 • Centene Corp • Hospital & medical service plans
Contract Type FiledFebruary 21st, 2023 Company Industry
AMENDMENT OF EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 21st, 2023 • Centene Corp • Hospital & medical service plans
Contract Type FiledFebruary 21st, 2023 Company IndustryTHIS AMENDMENT OF EXECUTIVE EMPLOYMENT AGREEMENT (the “Amendment”) is entered into as of February 20, 2023, by and between Centene Corporation, a Delaware corporation, together with its successors and assigns permitted under this Agreement (the “Company”), and Andrew Asher (the “Executive”).
AMENDMENT OF EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 21st, 2023 • Centene Corp • Hospital & medical service plans
Contract Type FiledFebruary 21st, 2023 Company IndustryTHIS AMENDMENT OF EXECUTIVE EMPLOYMENT AGREEMENT (the “Amendment”) is entered into as of February 20, 2023, by and between Centene Corporation, a Delaware corporation, together with its successors and assigns permitted under this Agreement (the “Company”), and Sarah M. London (the “Executive”).